West Pharmaceutical Services, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Eric Green
- Full Time Employees
- 10,800
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 530 Herman O. West Drive Exton PA United States of America 19341-1147
- IPO Date
- Mar 17, 1980
- CIK
- 0000105770
- Website
- westpharma.com
- Similar Companies
- Business
- West Pharmaceutical Services, Inc. is a global manufacturer and provider of integrated containment and delivery systems primarily for injectable drugs and healthcare products. The company's core offerings include stoppers and seals for injectable packaging systems; syringe and cartridge components; self-injection devices featuring patient-centric, connected health technologies; and advanced containment and delivery solutions such as the proprietary Daikyo Crystal Zenith polymer, a high-performance glass alternative suited for sensitive biologics. West also provides contract manufacturing services encompassing injection molding, contract assembly, and finished packaging through facilities in North America and Europe. Founded in 1923, the company is headquartered in Exton, Pennsylvania, and serves pharmaceutical, biologics, vaccine, and consumer healthcare markets worldwide. Recent major strategic developments at West include the launch of the West Synchrony™ Prefillable Syringe System, an innovative, fully verified system-level product designed specifically for biologics and vaccines scheduled for commercial availability in 2026. This system integrates syringe barrel, plunger, and needle components into a harmonized platform that accelerates regulatory submission and enhances supply chain reliability. In addition, West has strengthened its collaboration with Corning Incorporated, combining West’s NovaPure components and Daikyo Flurotec coating technology with Corning’s Valor® Glass and Velocity® Vials to develop advanced pharmaceutical packaging solutions that improve patient safety and drug stability. Furthermore, West has made a strategic investment in Latch Medical, a Dublin-based company specializing in next-generation vaccine and biologics delivery technology focused on intradermal delivery. West operates across more than 50 sites worldwide, including 25 manufacturing locations, supporting its expansive global supply chain. The company reported $2.89 billion in net sales for fiscal year 2024 and is publicly traded on the New York Stock Exchange under the ticker WST. It is also included in the Standard & Poor’s 500 index, reflecting its prominence as a trusted partner to established and emerging drug developers for the safe containment and delivery of life-saving medicines on a global scale. This comprehensive integration of innovative product offerings and strategic partnerships underscores West Pharmaceutical Services’ position as a leader in injectable drug delivery systems, supported by a nearly century-long heritage of technological advancement and manufacturing excellence.
Company News
Analyzing West Pharmaceutical Services (NYSE:WST) and Acutus Medical (NASDAQ:AFIB)
Benjamin Edwards Inc. Grows Position in West Pharmaceutical Services, Inc. $WST
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Recommendation of “Moderate Buy” from Brokerages
7,730 Shares in West Pharmaceutical Services, Inc. $WST Bought by Caisse de depot et placement du Quebec
West to Participate in Upcoming Investor Conferences
3,700 Shares in West Pharmaceutical Services, Inc. $WST Purchased by Barbara Oil Co.
Advisors Capital Management LLC Acquires New Shares in West Pharmaceutical Services, Inc. $WST
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
Conestoga SMid Cap Composite Q2 2026 Portfolio Review
West Pharmaceutical Services, Inc. $WST Holdings Increased by Dimensional Fund Advisors LP
West Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotia
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift
West Pharmaceutical Services Q2 Earnings Call Highlights
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth
West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcript
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum